Drug Index


Mechanism :

Flecainide has local anesthetic activity and belongs to the membrane stabilizing (Class 1) group of antiarrhythmic agents; it has electrophysiologic effects characteristic of the IC class of antiarrhythmics. Effects upon atrioventricular (AV) nodal conduction time and intra-atrial conduction times, are less pronounced than those on ventricular conduction velocity. Significant effects on refractory periods were observed only in the ventricle.
. The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibres. Flecainide is a sodium channel blocker, binding to voltage gated sodium channels. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole.
Possesses local anaesthetic and moderate negative inotropic effects.

Indication :

  • Arrhythmias
  • Supraventricular tachycardia- re-entry type
  • Ventricular ectopic
  • Ventricular tachycardia
  • WPW syndrome
  • Paroxysmal atrial fibrillation

Contraindications :

Flecainide is contraindicated in patients with pre-existing second- or third-degree AV block, or with right bundle branch block when associated with a left hemiblock (bifascicular block), unless a pacemaker is present to sustain the cardiac rhythm should complete heart block occur, and in the presence of cardiogenic shock or known hypersensitivity to the drug.

Dosing :

Under 6 months.
100 mg/m²/day orally in 2-3 divided doses. Start: 50 mg/m²/day in infants <6 months and 100 mg/m²/day in those above 6 months. Increase dose every 4 days. Max: 200 mg/m²/day.
Alternately start 1-3 mg/kg/day PO divided 8 hourly, increase to 3-6 mg/kg/day.
Note: After 5 doses/steady-state, obtain ECG after initiation or change of dose; obtain plasma trough Flecainide levels 1 hour pre-dose. Usual trough plasma levels: 0.2-1 mcg/mL.

Adverse Effect :

New or worsened arrhythmias in patients with PSVT and in patients with PAF, new or exacerbated ventricular arrhythmias in patients with PVCs, non-sustained or sustained VT, photosensitivity, allergic skin reactions, nausea, constipation, vomiting, elevation of serum alkaline phosphatase, serum transaminase levels, headache, transient dizziness, light-headedness, transient visual disturbances.

Interaction :

Beta blockers: The possibility of additive negative inotropic effects of beta blockers and flecainide.
Amiodarone: Plasma flecainide levels may increase two-fold or more in some patients.
Quinidine: Might increase the plasma concentrations of flecainide in patients that are on chronic flecainide therapy.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50See ‘Other Information
10-20See ‘Other Information
<10See ‘Other Information

Dose in Patients undergoing Renal Replacement Therapies
CAPD≈1% dialysed. Dose as in GFR<10 mL/min
HD≈1% dialysed. Dose as in GFR<10 mL/min
HDF/High fluxUnknown dialysability. Dose as in GFR<10 mL/min
CAV/VVHDMinimal removal. Dose as in GFR=10–20 mL/min

Hepatic Dose :

There is slower elimination in presence of liver disease. Frequent and early plasma drug monitoring is required for patients with severe hepatic disease. Adjust dosage at intervals of more than 4 days. Use in patients with hepatic impairment only if benefits clearly outweigh the risks.
03/13/2024 05:11:06 Flecainide
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0